β-synuclein inhibits α-synuclein aggregation: A possible role as an anti-Parkinsonian factor

Neuron

Volumn 32, Issue 2, 2001, Pages 213-223

  Hashimoto, Makoto ^a   Rockenstein, Edward ^a   Mante, Michael ^a   Mallory, Margaret ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; BETA SYNUCLEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOPRECIPITATION; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE;

EID: 0035950270     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(01)00462-7     Document Type: Article

References (60)

1. Wild-type but not Parkinson's disease-related ala-53→Thr mutant alpha synuclein protects neuronal cells from apoptotic stimuli
2. Parkinson's disease associated alpha-synuclein is more fibrillogenic than beta- and gamma synuclein and cannot cross-seed its homologues
3. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
4. Stabilization of alpha synuclein secondary structure upon binding to synthetic membranes
5. Review: Formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins
6. A Drosophila model of Parkinson's disease
7. Polyglutamine expansions: Proteolysis, chaperones, and the dangers of promiscuity
8. Alpha-synuclein and Parkinson's disease: Selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo
9. The core Alzheimer's peptide NAC forms amyloid fibrils, which seed and are seeded by β-amyloid: Is NAC a common trigger or target in neurodegenerative disease?
10. Interaction between Abeta(1-42) and Abeta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro
11. Alpha-synuclein in Lewy body disease and Alzheimer's disease
12. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease
13. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
14. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease
15. α-synuclein promotes mitochondrial deficiencies and oxidative stress
16. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease
17. Non-Aβ component of Alzheimer's disease amyloid (NAC) is amyloidogenic
18. α-synuclein forms a complex with transcription factor Elk-1
19. Identification of two distinct synucleins from human brain
20. Oxidative stress in Parkinson's disease and other neurodegenerative disorders
21. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalyzed cross-linking to Alzheimer-disease amyloid beta A4 peptide
22. Binding of Aβ to α- and β-synucleins: Identification of segments in α-synuclein/NAC precursor that bind Aβ and NAC
23. Stimulation of breast cancer invasion and metastasis by synuclein gamma
24. Alpha-synuclein membrane interactions and lipid specificity
25. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
26. Amyloid diseases: Abnormal protein aggregation in neurodegeneration
27. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
28. The role of synaptic proteins in neurodegenerative disorders
29. Recent advances in the understanding of the role of synaptic proteins in Alzheimer's disease and other neurodegenerative disorders
30. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease
31. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
32. βAmyloid peptides enhance αSynuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's and Parkinson's disease
33. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
34. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation
35. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
36. Intracellular polymerization. Disease severity and therapeutic predictions
37. Alpha- Synuclein shares physical and functional homology with 14-3-3 proteins
38. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity
39. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of C-terminal A beta fragment (residues 25-35)
40. Copper(II)-induced self-oligomerization of alpha-synuclein
41. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids: Structural analysis using site-directed mutagenesis
42. Mutation in the α-synuclein gene identified in families with Parkinson's disease
43. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype
44. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein
45. Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease
46. Altered expression of the synuclein family in Lewy body and Alzheimer's disease
47. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
48. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers
49. α-synuclein in Lewy bodies
50. Synoretin - A new protein belonging to the synuclein family
51. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
52. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders
53. Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human α-synuclein
54. Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and lewy body dementia
55. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease
56. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
57. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
58. Alpha-synuclein fibrillogenesis is nucleation dependent. Implications for the pathogenesis of Parkinson's disease
59. NACP, the precursor protein of non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation
60. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells